

BRITISH NUCLEAR MEDICINE SOCIETY

England & Wales - Charity number 1150234

Details

Other names BNMS

Status Registered

Legal form Charitable company

Company number [08082786](#)

Registered 2012-12-18

Register [View on the Charity Commission register](#)

Contact

Address PO Box 8599
Derby
Derbys
DE1 9PT

Phone 07385297906

Email contactus@bnms.org.uk

Website www.bnms.org.uk

Activities

Objects: THE ADVANCEMENT OF THE SCIENCE AND PUBLIC EDUCATION IN NUCLEAR MEDICINE.

Activities: engage with healthcare providers involved in the clinical use of radionuclides - provide resources and encourage the provision of education and training to support CPD - develop standards & guidelines for safe and effective practice - promote research and development - provide greater information for the benefit of patients - Promote and support the recertification/ revalidation of practitioners.

Classification

- **How:** Makes Grants To Individuals, Makes Grants To Organisations, Provides Advocacy/advice/information, Sponsors Or Undertakes Research
- **What:** Education/training, The Advancement Of Health Or Saving Of Lives, Arts/culture/heritage/science
- **Who:** The General Public/mankind

Geography

- Northern Ireland
- Scotland
- Throughout England And Wales

Finances

Period end	Income	Expenditure	Assets	Employees
2024-12-31	£526,217	£542,381	£479,992	3
2023-12-31	£513,663	£422,297	£496,156	3
2022-12-31	£389,185	£339,483	-	-
2021-12-31	£200,549	£171,070	-	-
2020-12-31	£153,429	£170,544	-	-

Trustees

Name	Role	Appointed
Charanjit Singh Kalirai		2017-05-22
Dr Amy Eccles		2025-05-20
Dr Arum Parthipun		2020-09-23
Dr Kshama Wechalekar		2024-05-13
Dr Vineet Prakash		2024-05-13
Jillian Croasdale		2015-04-28
Professor Sabina Dizdarevic		2024-05-13
Richard Christopher Fernandez		2022-05-17

BRITISH NUCLEAR MEDICINE SOCIETY

England & Wales - Charity number 1150234

Accounts

REGISTERED COMPANY NUMBER: 08082786 (England and Wales)
REGISTERED CHARITY NUMBER: 1150234

**REPORT OF THE TRUSTEES AND
FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024
FOR
BRITISH NUCLEAR MEDICINE SOCIETY**

E R Grove & Co Limited
Grove House
Coombs Wood Court
Steel Park Road
Halesowen
West Midlands
B62 8BF

BRITISH NUCLEAR MEDICINE SOCIETY

**CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024**

	Page
Report of the Trustees	1 to 4
Independent Examiner's Report	5
Statement of Financial Activities	6
Balance Sheet	7
Cash Flow Statement	8
Notes to the Cash Flow Statement	9
Notes to the Financial Statements	10 to 15
Detailed Statement of Financial Activities	16 to 17

BRITISH NUCLEAR MEDICINE SOCIETY

REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31 DECEMBER 2024

The trustees who are also directors of the charity for the purposes of the Companies Act 2006, present their report with the financial statements of the charity for the year ended 31 December 2024. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).

OBJECTIVES AND ACTIVITIES

Objectives and aims

British Nuclear Medicine Society is dedicated to raising the profile of nuclear medicine and to promote the multidisciplinary practice of high quality nuclear medicine for the benefit of patients.

Significant activities

In order for the charity to achieve its aim BNMS engage in the following activities:

- Raising the profile of nuclear medicine through the website, scientific meetings and attendance of careers fairs.
- Engaging with other professional organisations, including British Institute of Radiology, British Cardiology Society, Institute of Physics and Engineering in Medicine, Royal College of Physicians, Royal College of Radiologists, Royal College of Surgeons, Royal College of Nursing, Society and College of Radiographers and Society of Radiological Protection.
- Providing a forum for the communication of advances in nuclear medicine through annual and regional scientific meetings, Nuclear Medicine Communications (the official BNMS journal) and the BNMS website.
- Leading in the provision of education and training to support the development of nuclear medicine
- Representing the specialty on relevant official bodies and advisory committees
- Developing and promoting standards and guidelines for the safe practice of nuclear medicine.
- Promoting nuclear medicine research and development by engaging with academic institutions and industry to promote research leading to new developments and improvements in clinical practice.

Public benefit

The public benefits from the activities of the British Nuclear Medicine Society through the pursuit of its specific objectives including the development and promotion of standards and guidelines for the safe and effective practice of nuclear medicine, the promotion of nuclear medicine research and development and the provision of greater information for the public on the BNMS website.

BRITISH NUCLEAR MEDICINE SOCIETY

REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31 DECEMBER 2024

OBJECTIVES AND ACTIVITIES

Our committees

Professional Standards Committee

The Professional Standards Committee advises the Officers and Council of BNMS on the development and implementation on professional standards and audit. They develop, promote, publicise and review guidelines for the delivery of nuclear medicine services and procedures and are also responsible for developing patient information in nuclear medicine.

Scientific and Education Committee

The British Nuclear Medicine Society (BNMS) established the combined Scientific Committee and Education Committee in 2016.

The mandate of the Scientific and Education Committee is to develop an education and scientific programme, nominate invited speakers and the chairs of sessions.

The remit of this committee is to provide resources and encourage the provision of education and training to support Continuing Professional Development/Continuous Medical Education and work towards revalidation. The Education Committee is Multidisciplinary, consisting of Nuclear Medicine Physicians, Clinical Practitioners, Physicists, Nurses and Radiopharmacists.

Research & Innovation Committee

Research & Innovation Committee (RIC) reports to BNMS council and governs BNMS Research Champions network and links to the MRT Research Committee.

The purpose of the RIC is to provide integrated clinical, scientific and operational leadership and management/oversight of delivery of the BNMS Research Strategy.

The roles of the Research & Innovation Committee are to develop and deliver BNMS Research Strategy with aims:

1. To enhance radionuclide research delivery in the United Kingdom leading to service improvement and better care of patients. To accomplish this the BNMS will outline research priority areas highlighting current unmet needs. It will investigate through research sessions and workshops on-line and at face-to-face meetings on how best its multi professional membership can develop projects and achieve funding from the appropriate bodies. The BNMS will facilitate research networks through the BNMS website and offer peer support and review through face-to-face meetings at the BNMS conferences. It will endeavour to contribute to and work with the professional bodies involved in research, the UK Colleges, the charities, and the national and international Nuclear Medicine societies. It will foster links with research partners including the UK PET Network the CRUK Radiation Network, RadNet, the National Cancer Imaging Translational Accelerator (NCITA) and Industry Academic partnership via Industry forum held 2-3 times a year.

2. To build up an evidence base for new radionuclide molecular diagnostic and therapeutic procedures. The BNMS research network group is developing a data base of current research in the UK and a data base of available research funding. It is also developing a data base to ethically collect data from ongoing research studies.

UK MRT Consortium

The UK molecular radiotherapy consortium is a group comprised of both healthcare professionals and patient advocates who are directly and passionately associated in delivering and caring for patients undergoing molecular radiotherapy based treatments.

The UK MRT Consortium are the first organisation to serve current and future patients who may find the need to receive such types of treatment to help maintain and sustain both quality and duration of life.

By bringing members and fellows of both the British Nuclear Medicine Society and the Royal College of Radiologists together along with patient advocates and nationally recognised charities, we will endeavour to ensure that all parts of the United Kingdom will have equitable access to current and future therapies, raise public awareness of such treatments, design and encourage activity in nationally recognised molecular radiotherapy trials.

Trainee Committee

Aims of BNMS Medical Trainee Committee

Increase awareness of diagnostic and therapeutic Nuclear Medicine amongst doctors-in-training and medical students.

Provide educational content for doctors-in-training and medical students to aid their understanding of working in Nuclear Medicine and the training pathways.

Provide opportunities for doctors-in -training and medical students to engage with the BNMS and improve their application for the specialties/training numbers.

Radiographers Technologists and Nurses

The BNMS Radiographers, Technologists & Nurses' Committee:-

- Represents Radiographers, Technologists & Nurses on the BNMS Council
- Organises sessions at the BNMS Meetings
- Provides advice and opinion on issues affecting all 3 groups

BRITISH NUCLEAR MEDICINE SOCIETY

REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31 DECEMBER 2024

OBJECTIVES AND ACTIVITIES

Objectives

- To unite Radiographers, Technologists & Nurses working in Nuclear Medicine into one professional association.
- To encourage professional development and education of these 3 groups by:
 - * Co-operating with existing organisations providing education and training
 - * Supporting and endorsing existing organisations providing education and training.
- To represent the group within the British Nuclear Medicine Society, including participation in organisation of sessions at the Spring and Autumn BNMS meetings.

ACHIEVEMENT AND PERFORMANCE

Charitable activities

The British Nuclear Medicine Society held three scientific and educational meetings this year around the UK, the results of which are as follows:

	Spring Belfast £	Autumn Norwich £	Online Educational £	Total £
Income				
Commercial exhibition income	202,375	18,336	5,008	225,718
Annual conference delegate registration fees	<u>112,809</u>	<u>13,840</u>	<u>8,366</u>	<u>135,015</u>
	315,184	32,177	13,374	360,734
Less: Scientific meeting expenses	<u>261,309</u>	<u>21,523</u>	<u>12,966</u>	<u>295,799</u>
Surplus	<u><u>53,874</u></u>	<u><u>10,653</u></u>	<u><u>408</u></u>	<u><u>64,935</u></u>

Fundraising activities

The British Nuclear Medicine Society generates income from membership fees, from royalties received through "Nuclear Medicine Communications" (the scientific journal of the BNMS) as well registration and exhibitor fees from those attendees at the annual and educational meetings of the Society.

FINANCIAL REVIEW

Reserves policy

The trustees aim to maintain general reserve levels at the equivalent of at least 18 months expenditure. The unrestricted fund balance (excluding designated funds) at the year end of £466,821 is above this level and continues to be carefully monitored by the trustees.

FUTURE PLANS

The society will continue to promote the multidisciplinary practice of nuclear medicine for the benefit of patients. It plans to continue holding regular meetings throughout the country and will further encourage regional networks.

STRUCTURE, GOVERNANCE AND MANAGEMENT

Governing document

The charity is controlled by its governing document, a deed of trust, and constitutes a limited company, limited by guarantee, as defined by the Companies Act 2006.

REFERENCE AND ADMINISTRATIVE DETAILS

Registered Company number

08082786 (England and Wales)

Registered Charity number

1150234

Registered office

Royal College of Physicians
11 St Andrews Place
Regents Park
London
NW1 4LE

BRITISH NUCLEAR MEDICINE SOCIETY

**REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31 DECEMBER 2024**

Trustees

Who are also directors

Mrs J Croasdale

Dr R Graham (resigned 13 May 2024)

Dr S Redman (resigned 20 May 2025)

Mr C S Kalirai

Mrs S Dizdarevic (appointed 13 May 2024)

Radiopharmacist

Radiologist

Radiologist

Clinical Scientist

Professor

Independent Examiner

E R Grove & Co Limited

Grove House

Coombs Wood Court

Steel Park Road

Halesowen

West Midlands

B62 8BF

Approved by order of the board of trustees on 8 May 2025 and signed on its behalf by:

Mr C S Kalirai - Trustee

INDEPENDENT EXAMINER'S REPORT TO THE TRUSTEES OF BRITISH NUCLEAR MEDICINE SOCIETY

Independent examiner's report to the trustees of British Nuclear Medicine Society ('the Company')

I report to the charity trustees on my examination of the accounts of the Company for the year ended 31 December 2024.

Responsibilities and basis of report

As the charity's trustees of the Company (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under Section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under Section 145(5) (b) of the 2011 Act.

Independent examiner's statement

Since your charity's gross income exceeded £250,000 your examiner must be a member of a listed body. I can confirm that I am qualified to undertake the examination because I am a member of the Institute of Chartered Accountants in England and Wales, which is one of the listed bodies.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

1. accounting records were not kept in respect of the Company as required by Section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of Section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities (applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

Steven Lomas

E R Grove & Co Limited
Grove House
Coombs Wood Court
Steel Park Road
Halesowen
West Midlands
B62 8BF

8 May 2025

BRITISH NUCLEAR MEDICINE SOCIETY

**STATEMENT OF FINANCIAL ACTIVITIES
FOR THE YEAR ENDED 31 DECEMBER 2024**

	Notes	Unrestricted fund £	Restricted fund £	2024 Total funds £	2023 Total funds £
INCOME AND ENDOWMENTS FROM					
Donations and legacies	2	-	-	-	4,400
Other trading activities	3	441,142	-	441,142	412,766
Investment income	4	9,414	207	9,621	5,933
Other income		<u>75,454</u>	<u>-</u>	<u>75,454</u>	<u>90,564</u>
Total		<u>526,010</u>	<u>207</u>	<u>526,217</u>	<u>513,663</u>
EXPENDITURE ON					
Raising funds	5	<u>542,381</u>	<u>-</u>	<u>542,381</u>	<u>422,297</u>
NET INCOME/(EXPENDITURE)		(16,371)	207	(16,164)	91,366
RECONCILIATION OF FUNDS					
Total funds brought forward		<u>481,883</u>	<u>14,273</u>	<u>496,156</u>	<u>404,790</u>
TOTAL FUNDS CARRIED FORWARD		<u><u>465,512</u></u>	<u><u>14,480</u></u>	<u><u>479,992</u></u>	<u><u>496,156</u></u>

The notes form part of these financial statements

BRITISH NUCLEAR MEDICINE SOCIETY

**BALANCE SHEET
31 DECEMBER 2024**

	Notes	Unrestricted fund £	Restricted fund £	2024 Total funds £	2023 Total funds £
FIXED ASSETS					
Tangible assets	11	1,644	-	1,644	2,415
CURRENT ASSETS					
Debtors	12	243,023	-	243,023	168,525
Cash at bank		<u>405,521</u>	<u>14,480</u>	<u>420,001</u>	<u>433,145</u>
		648,544	14,480	663,024	601,670
CREDITORS					
Amounts falling due within one year	13	(184,676)	-	(184,676)	(107,929)
		<u>463,868</u>	<u>14,480</u>	<u>478,348</u>	<u>493,741</u>
NET CURRENT ASSETS					
		465,512	14,480	479,992	496,156
TOTAL ASSETS LESS CURRENT LIABILITIES					
		<u>465,512</u>	<u>14,480</u>	<u>479,992</u>	<u>496,156</u>
FUNDS	14				
Unrestricted funds				465,512	481,883
Restricted funds				<u>14,480</u>	<u>14,273</u>
TOTAL FUNDS				<u>479,992</u>	<u>496,156</u>

The charitable company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2024 in accordance with Section 476 of the Companies Act 2006.

The trustees acknowledge their responsibilities for

- (a) ensuring that the charitable company keeps accounting records that comply with Sections 386 and 387 of the Companies Act 2006 and
- (b) preparing financial statements which give a true and fair view of the state of affairs of the charitable company as at the end of each financial year and of its surplus or deficit for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the charitable company.

These financial statements have been prepared in accordance with the provisions applicable to charitable companies subject to the small companies regime.

The financial statements were approved by the Board of Trustees and authorised for issue on 8 May 2025 and were signed on its behalf by:

Mr C S Kalirai - Trustee

The notes form part of these financial statements

BRITISH NUCLEAR MEDICINE SOCIETY

**CASH FLOW STATEMENT
FOR THE YEAR ENDED 31 DECEMBER 2024**

	Notes	2024 £	2023 £
Cash flows from operating activities			
Cash generated from operations	1	<u>(22,766)</u>	<u>80,923</u>
Net cash (used in)/provided by operating activities		<u>(22,766)</u>	<u>80,923</u>
Cash flows from investing activities			
Purchase of tangible fixed assets		1	(433)
Interest received		<u>9,621</u>	<u>5,933</u>
Net cash provided by investing activities		<u>9,622</u>	<u>5,500</u>
Change in cash and cash equivalents in the reporting period		(13,144)	86,423
Cash and cash equivalents at the beginning of the reporting period		<u>433,145</u>	<u>346,722</u>
Cash and cash equivalents at the end of the reporting period		<u><u>420,001</u></u>	<u><u>433,145</u></u>

The notes form part of these financial statements

BRITISH NUCLEAR MEDICINE SOCIETY

**NOTES TO THE CASH FLOW STATEMENT
FOR THE YEAR ENDED 31 DECEMBER 2024**

1. RECONCILIATION OF NET (EXPENDITURE)/INCOME TO NET CASH FLOW FROM OPERATING ACTIVITIES

	2024 £	2023 £
Net (expenditure)/income for the reporting period (as per the Statement of Financial Activities)	(16,164)	91,366
Adjustments for:		
Depreciation charges	770	1,147
Interest received	(9,621)	(5,933)
(Increase)/decrease in debtors	(74,498)	20,748
Increase/(decrease) in creditors	<u>76,747</u>	<u>(26,405)</u>
Net cash (used in)/provided by operations	<u>(22,766)</u>	<u>80,923</u>

2. ANALYSIS OF CHANGES IN NET FUNDS

	At 1.1.24 £	Cash flow £	At 31.12.24 £
Net cash			
Cash at bank	<u>433,145</u>	<u>(13,144)</u>	<u>420,001</u>
	<u>433,145</u>	<u>(13,144)</u>	<u>420,001</u>
Total	<u>433,145</u>	<u>(13,144)</u>	<u>420,001</u>

BRITISH NUCLEAR MEDICINE SOCIETY

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024

1. ACCOUNTING POLICIES

Basis of preparing the financial statements

The financial statements of the charitable company, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Income

All income is recognised in the Statement of Financial Activities once the charity has entitlement to the funds, it is probable that the income will be received and the amount can be measured reliably.

Exhibition income is recognised in the Statement of Financial Activities in the year that the exhibition is held.

Grants and donations are only recognised in the statement of Financial Activity when the charity has unconditional entitlement to the resources. Where the donor imposes conditions that the resource is expended in a future accounting period, income is recorded as deferred income at the balance sheet date and a creditor is included under deferred income.

Expenditure

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.

Exhibition expense are recognised in the Statement of Financial Activities in the year that the exhibition is held.

Tangible fixed assets

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Fixtures and fittings	- 15% on reducing balance
Computer equipment	- 33% on reducing balance

Taxation

The charity is exempt from corporation tax on its charitable activities.

Fund accounting

Unrestricted funds are available of use at the discretion of the trustees In furtherance of the general objectives of the charity and which have not been designated for other purposes.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors which have been raised by the Charity for particular purposes. The cost of raising and administering such funds are charged against the specific fund.

Further explanation of the nature and purpose of each fund is included in the notes to the financial statements.

Pension costs and other post-retirement benefits

The charitable company operates a defined contribution pension scheme. Contributions payable to the charitable company's pension scheme are charged to the Statement of Financial Activities in the period to which they relate.

BRITISH NUCLEAR MEDICINE SOCIETY

**NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 DECEMBER 2024**

2. DONATIONS AND LEGACIES					
			2024	2023	
			£	£	
Donations			<u>-</u>	<u>4,400</u>	
3. OTHER TRADING ACTIVITIES					
			2024	2023	
			£	£	
Commercial exhibition income			225,718	187,021	
Annual conference delegate registration fees			135,015	148,480	
Commission received			1,288	4,124	
Royalties received			75,835	71,861	
Other project income			<u>3,286</u>	<u>1,280</u>	
			<u>441,142</u>	<u>412,766</u>	
4. INVESTMENT INCOME					
			2024	2023	
			£	£	
Deposit account interest			<u>9,621</u>	<u>5,933</u>	
5. RAISING FUNDS					
Raising donations and legacies					
			2024	2023	
			£	£	
Support costs			<u>121,255</u>	<u>141,820</u>	
Other trading activities					
			2024	2023	
			£	£	
Purchases			300,138	239,557	
Awards and prizes			2,748	1,432	
Journal subscriptions			74,029	39,488	
Support costs			<u>44,211</u>	<u>-</u>	
			<u>421,126</u>	<u>280,477</u>	
Aggregate amounts			<u>542,381</u>	<u>422,297</u>	
6. SUPPORT COSTS					
	Management	Finance	Other	Governance	Totals
	£	£	£	costs	£
				£	
Raising donations and legacies	121,015	-	-	240	121,255
Other trading activities	<u>32,944</u>	<u>3,578</u>	<u>770</u>	<u>6,919</u>	<u>44,211</u>
	<u>153,959</u>	<u>3,578</u>	<u>770</u>	<u>7,159</u>	<u>165,466</u>

BRITISH NUCLEAR MEDICINE SOCIETY

**NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 DECEMBER 2024**

7. NET INCOME/(EXPENDITURE)

Net income/(expenditure) is stated after charging/(crediting):

	2024	2023
	£	£
Other assurance services	5,360	3,831
Depreciation - owned assets	<u>771</u>	<u>1,146</u>

8. TRUSTEES' REMUNERATION AND BENEFITS

There were no trustees' remuneration or other benefits for the year ended 31 December 2024 nor for the year ended 31 December 2023.

Trustees' expenses

Payments totalling £4,761 (2022: £1,645) were made to trustees to reimburse travel costs to conferences and council meetings.

9. STAFF COSTS

	2024	2023
	£	£
Wages and salaries	117,999	86,558
Other pension costs	<u>3,016</u>	<u>3,079</u>
	<u>121,015</u>	<u>89,637</u>

The average monthly number of employees during the year was as follows:

	2024	2023
Administrative	<u>3</u>	<u>3</u>

No employees received emoluments in excess of £60,000.

10. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES

	Unrestricted fund £	Restricted fund £	Total funds £
INCOME AND ENDOWMENTS FROM			
Donations and legacies	4,400	-	4,400
Other trading activities	412,849	(83)	412,766
Investment income	5,768	165	5,933
Other income	<u>90,564</u>	<u>-</u>	<u>90,564</u>
Total	<u>513,581</u>	<u>82</u>	<u>513,663</u>
EXPENDITURE ON			
Raising funds	<u>422,080</u>	<u>217</u>	<u>422,297</u>
NET INCOME/(EXPENDITURE)	91,501	(135)	91,366
RECONCILIATION OF FUNDS			
Total funds brought forward	<u>390,382</u>	<u>14,408</u>	<u>404,790</u>
TOTAL FUNDS CARRIED FORWARD	481,883	14,273	496,156

=====

=====

=====

BRITISH NUCLEAR MEDICINE SOCIETY

**NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 DECEMBER 2024**

11. TANGIBLE FIXED ASSETS

	Fixtures and fittings £	Computer equipment £	Totals £
COST			
At 1 January 2024 and 31 December 2024	<u>905</u>	<u>30,534</u>	<u>31,439</u>
DEPRECIATION			
At 1 January 2024	718	28,306	29,024
Charge for year	<u>28</u>	<u>743</u>	<u>771</u>
At 31 December 2024	<u>746</u>	<u>29,049</u>	<u>29,795</u>
NET BOOK VALUE			
At 31 December 2024	<u>159</u>	<u>1,485</u>	<u>1,644</u>
At 31 December 2023	<u>187</u>	<u>2,228</u>	<u>2,415</u>

12. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2024 £	2023 £
Trade debtors	76,022	49,542
Other debtors	73,955	39,132
VAT	10,541	-
Prepayments and accrued income	<u>82,505</u>	<u>79,851</u>
	<u>243,023</u>	<u>168,525</u>

13. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2024 £	2023 £
Trade creditors	59,558	4,160
Social security and other taxes	2,539	1,959
VAT	-	13,989
Other creditors	116,877	82,440
Accrued expenses	<u>5,702</u>	<u>5,381</u>
	<u>184,676</u>	<u>107,929</u>

14. MOVEMENT IN FUNDS

	At 1.1.24 £	Net movement in funds £	At 31.12.24 £
Unrestricted funds			
General fund	481,883	(16,371)	465,512
Restricted funds			
Ross Breen Fund	14,273	207	14,480
TOTAL FUNDS	<u>496,156</u>	<u>(16,164)</u>	<u>479,992</u>

BRITISH NUCLEAR MEDICINE SOCIETY

**NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 DECEMBER 2024**

14. MOVEMENT IN FUNDS - continued

Net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	526,010	(542,381)	(16,371)
Restricted funds			
Ross Breen Fund	207	-	207
	<hr/>	<hr/>	<hr/>
TOTAL FUNDS	<u>526,217</u>	<u>(542,381)</u>	<u>(16,164)</u>

Comparatives for movement in funds

	At 1.1.23 £	Net movement in funds £	At 31.12.23 £
Unrestricted funds			
General fund	390,382	91,501	481,883
Restricted funds			
Ross Breen Fund	14,408	(135)	14,273
	<hr/>	<hr/>	<hr/>
TOTAL FUNDS	<u>404,790</u>	<u>91,366</u>	<u>496,156</u>

Comparative net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	513,581	(422,080)	91,501
Restricted funds			
Ross Breen Fund	82	(217)	(135)
	<hr/>	<hr/>	<hr/>
TOTAL FUNDS	<u>513,663</u>	<u>(422,297)</u>	<u>91,366</u>

A current year 12 months and prior year 12 months combined position is as follows:

	At 1.1.23 £	Net movement in funds £	At 31.12.24 £
Unrestricted funds			
General fund	390,382	75,130	465,512
Restricted funds			
Ross Breen Fund	14,408	72	14,480
	<hr/>	<hr/>	<hr/>
TOTAL FUNDS	<u>404,790</u>	<u>75,202</u>	<u>479,992</u>

BRITISH NUCLEAR MEDICINE SOCIETY

**NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 DECEMBER 2024**

14. MOVEMENT IN FUNDS - continued

A current year 12 months and prior year 12 months combined net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	1,039,591	(964,461)	75,130
Restricted funds			
Ross Breen Fund	289	(217)	72
	<hr/>	<hr/>	<hr/>
TOTAL FUNDS	<u>1,039,880</u>	<u>(964,678)</u>	<u>75,202</u>

The Ros Breen Fund was established in memory of Ros Breen, who was Superintendent Radiographer in Nuclear Medicine at Southampton General Hospital. The fund is invested in a capital reserve bank account and the interest earned is then used to provide grants to members of the Technology Group.

15. RELATED PARTY DISCLOSURES

There were no related party transactions for the year ended 31 December 2024.

BRITISH NUCLEAR MEDICINE SOCIETY

**DETAILED STATEMENT OF FINANCIAL ACTIVITIES
FOR THE YEAR ENDED 31 DECEMBER 2024**

	2024 £	2023 £
INCOME AND ENDOWMENTS		
Donations and legacies		
Donations	-	4,400
Other trading activities		
Commercial exhibition income	225,718	187,021
Annual conference delegate registration fees	135,015	148,480
Commission received	1,288	4,124
Royalties received	75,835	71,861
Other project income	<u>3,286</u>	<u>1,280</u>
	441,142	412,766
Investment income		
Deposit account interest	9,621	5,933
Other income		
Members subscriptions	<u>75,454</u>	<u>90,564</u>
Total incoming resources	526,217	513,663
EXPENDITURE		
Other trading activities		
Scientific meeting expenses	295,799	238,607
Other project expenses	4,339	950
Awards and prizes	2,748	1,432
Journal subscriptions	<u>74,029</u>	<u>39,488</u>
	376,915	280,477
Support costs		
Management		
Wages and social security	117,999	86,558
Pensions	3,016	3,079
Rent	1,312	1,280
Insurance	1,112	1,033
Subscriptions	2,080	678
Telephone	681	709
Postage and stationery	658	867
General meeting and travelling expenses	13,907	19,711
Sundries	247	355
Computer costs	<u>12,947</u>	<u>19,398</u>
	153,959	133,668
Finance		
Bank charges	1,646	1,681
Card charges	446	-
Direct debit processing costs	<u>1,486</u>	<u>1,253</u>
	3,578	2,934
Other		
Fixtures and fittings	28	33
Carried forward	28	33

This page does not form part of the statutory financial statements

BRITISH NUCLEAR MEDICINE SOCIETY

**DETAILED STATEMENT OF FINANCIAL ACTIVITIES
FOR THE YEAR ENDED 31 DECEMBER 2024**

	2024 £	2023 £
Other		
Brought forward	28	33
Computer equipment	<u>742</u>	<u>1,114</u>
	770	1,147
Governance costs		
Auditors' remuneration for non audit work	5,360	3,831
Payroll costs	240	240
Professional fees	250	-
Bookkeeping	<u>1,309</u>	<u>-</u>
	<u>7,159</u>	<u>4,071</u>
Total resources expended	<u>542,381</u>	<u>422,297</u>
Net (expenditure)/income	<u><u>(16,164)</u></u>	<u><u>91,366</u></u>

This page does not form part of the statutory financial statements

BRITISH NUCLEAR MEDICINE SOCIETY

England & Wales - Charity number 1150234

Accounts

REGISTERED COMPANY NUMBER: 08082786 (England and Wales)
REGISTERED CHARITY NUMBER: 1150234

**REPORT OF THE TRUSTEES AND
FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023
FOR
BRITISH NUCLEAR MEDICINE SOCIETY**

E R Grove & Co Limited
Grove House
Coombs Wood Court
Steel Park Road
Halesowen
West Midlands
B62 8BF

BRITISH NUCLEAR MEDICINE SOCIETY

**CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023**

	Page
Report of the Trustees	1 to 3
Independent Examiner's Report	4
Statement of Financial Activities	5
Balance Sheet	6
Cash Flow Statement	7
Notes to the Cash Flow Statement	8
Notes to the Financial Statements	9 to 14
Detailed Statement of Financial Activities	15 to 16

BRITISH NUCLEAR MEDICINE SOCIETY

REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31 DECEMBER 2023

The trustees who are also directors of the charity for the purposes of the Companies Act 2006, present their report with the financial statements of the charity for the year ended 31 December 2023. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).

OBJECTIVES AND ACTIVITIES

Objectives and aims

British Nuclear Medicine Society is dedicated to promoting the multidisciplinary practice of high quality nuclear medicine for the benefit of patients.

The specific objectives of the British Nuclear Medicine Society are to:

- 1 Raise the profile of nuclear medicine
- 2 Engage with all health care providers involved in the clinical use of radionuclides
- 3 Provide a forum for the communication of advances in nuclear medicine
- 4 Provide resources and encourage the provision of education and training to support continuing professional development.
- 5 Represent nuclear medicine with official bodies and on advisory committees
- 6 Develop and promote standards and guidelines for the safe and effective practice of nuclear medicine
- 7 Promote nuclear medicine research and development
- 8 Improve the level of support to isolated departments
- 9 Provide greater information for the benefit of patients
- 10 Promote and support the recertification/revalidation of practitioners
- 11 Maintain an appropriate charitable status.

Significant activities

In order for the charity to achieve its aim BNMS engage in the following activities:

- Raising the profile of nuclear medicine through the website, scientific meetings and attendance of careers fairs.
- Engaging with other professional organisations, including British Institute of Radiology, British Cardiology Society, Institute of Physics and Engineering in Medicine, Royal College of Physicians, Royal College of Radiologists, Royal College of Surgeons, Royal College of Nursing, Society and College of Radiographers and Society of Radiological Protection.
- Providing a forum for the communication of advances in nuclear medicine through annual and regional scientific meetings, Nuclear Medicine Communications (the official BNMS journal) and the BNMS website.
- Leading in the provision of education and training to support the development of nuclear medicine
- Representing the specialty on relevant official bodies and advisory committees
- Developing and promoting standards and guidelines for the safe practice of nuclear medicine.
- Promoting nuclear medicine research and development by engaging with academic institutions and industry to promote research leading to new developments and improvements in clinical practice.

Public benefit

The public benefits from the activities of the British Nuclear Medicine Society through the pursuit of its specific objectives including the development and promotion of standards and guidelines for the safe and effective practice of nuclear medicine, the promotion of nuclear medicine research and development and the provision of greater information for the public on the BNMS website.

BRITISH NUCLEAR MEDICINE SOCIETY

REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31 DECEMBER 2023

ACHIEVEMENT AND PERFORMANCE

Charitable activities

The British Nuclear Medicine Society held three scientific and educational meetings this year around the UK, the results of which are as follows:

	Spring Harrogate £	Autumn London £	Online Educational £	Total £
Income				
Commercial exhibition income	159,973	26,048	1,000	187,021
Annual conference delegate registration fees	105,468	25,466	17,546	148,480
	<hr/>	<hr/>	<hr/>	<hr/>
	265,441	51,514	18,546	335,501
Less: Scientific meeting expenses	187,789	43,683	7,135	238,607
	<hr/>	<hr/>	<hr/>	<hr/>
Surplus	77,652	7,831	11,411	96,894
	<hr/> <hr/>	<hr/> <hr/>	<hr/> <hr/>	<hr/> <hr/>

Fundraising activities

The British Nuclear Medicine Society generates income from membership fees, from royalties received through "Nuclear Medicine Communications" (the scientific journal of the BNMS) as well registration and exhibitor fees from those attendees at the annual and educational meetings of the Society.

FUTURE PLANS

The society will continue to promote the multidisciplinary practice of nuclear medicine for the benefit of patients. It plans to continue holding regular meetings throughout the country and will further encourage regional networks.

STRUCTURE, GOVERNANCE AND MANAGEMENT

Governing document

The charity is controlled by its governing document, a deed of trust, and constitutes a limited company, limited by guarantee, as defined by the Companies Act 2006.

REFERENCE AND ADMINISTRATIVE DETAILS

Registered Company number

08082786 (England and Wales)

Registered Charity number

1150234

Registered office

Royal College of Physicians
11 St Andrews Place
Regents Park
London
NW1 4LE

Trustees

Who are also directors

Mrs J Croasdale

Dr R Graham

Dr S Redman

Dr J R Buscombe (Resigned 17 May 22)

Mr C S Kalirai (appointed 17 May 22)

Radiopharmacist

Radiologist

Radiologist

Nuclear Medicine Physician

Clinical Scientist

Independent Examiner

E R Grove & Co Limited
Grove House
Coombs Wood Court
Steel Park Road
Halesowen
West Midlands
B62 8BF

Approved by order of the board of trustees on 8 May 2024 and signed on its behalf by:

BRITISH NUCLEAR MEDICINE SOCIETY
REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31 DECEMBER 2023

Mr C S Kalirai - Trustee

INDEPENDENT EXAMINER'S REPORT TO THE TRUSTEES OF BRITISH NUCLEAR MEDICINE SOCIETY

Independent examiner's report to the trustees of British Nuclear Medicine Society ('the Company')

I report to the charity trustees on my examination of the accounts of the Company for the year ended 31 December 2023.

Responsibilities and basis of report

As the charity's trustees of the Company (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under Section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under Section 145(5) (b) of the 2011 Act.

Independent examiner's statement

Since your charity's gross income exceeded £250,000 your examiner must be a member of a listed body. I can confirm that I am qualified to undertake the examination because I am a member of the Institute of Chartered Accountants in England and Wales, which is one of the listed bodies.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

1. accounting records were not kept in respect of the Company as required by Section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of Section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities (applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

Steven Lomas

E R Grove & Co Limited
Grove House
Coombs Wood Court
Steel Park Road
Halesowen
West Midlands
B62 8BF

8 May 2024

BRITISH NUCLEAR MEDICINE SOCIETY

**STATEMENT OF FINANCIAL ACTIVITIES
FOR THE YEAR ENDED 31 DECEMBER 2023**

	Notes	Unrestricted fund £	Restricted fund £	2023 Total funds £	2022 Total funds £
INCOME AND ENDOWMENTS FROM					
Donations and legacies	2	4,400	-	4,400	3,500
Other trading activities	3	412,849	(83)	412,766	319,943
Investment income	4	5,768	165	5,933	1,706
Other income		90,564	-	90,564	64,036
Total		<u>513,581</u>	<u>82</u>	<u>513,663</u>	<u>389,185</u>
EXPENDITURE ON					
Raising funds	5	422,080	217	422,297	339,483
NET INCOME/(EXPENDITURE)		91,501	(135)	91,366	49,702
RECONCILIATION OF FUNDS					
Total funds brought forward		390,382	14,408	404,790	355,088
TOTAL FUNDS CARRIED FORWARD		<u><u>481,883</u></u>	<u><u>14,273</u></u>	<u><u>496,156</u></u>	<u><u>404,790</u></u>

The notes form part of these financial statements

BRITISH NUCLEAR MEDICINE SOCIETY

**BALANCE SHEET
31 DECEMBER 2023**

	Notes	Unrestricted fund £	Restricted fund £	2023 Total funds £	2022 Total funds £
FIXED ASSETS					
Tangible assets	11	2,415	-	2,415	3,129
CURRENT ASSETS					
Debtors	12	168,525	-	168,525	189,273
Cash at bank		418,872	14,273	433,145	346,722
		<u>587,397</u>	<u>14,273</u>	<u>601,670</u>	<u>535,995</u>
CREDITORS					
Amounts falling due within one year	13	(107,929)	-	(107,929)	(134,334)
NET CURRENT ASSETS		<u>479,468</u>	<u>14,273</u>	<u>493,741</u>	<u>401,661</u>
TOTAL ASSETS LESS CURRENT LIABILITIES		<u>481,883</u>	<u>14,273</u>	<u>496,156</u>	<u>404,790</u>
NET ASSETS		<u>481,883</u>	<u>14,273</u>	<u>496,156</u>	<u>404,790</u>
FUNDS	14				
Unrestricted funds				481,883	390,382
Restricted funds				14,273	14,408
TOTAL FUNDS				<u>496,156</u>	<u>404,790</u>

The charitable company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2023.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2023 in accordance with Section 476 of the Companies Act 2006.

The trustees acknowledge their responsibilities for

- (a) ensuring that the charitable company keeps accounting records that comply with Sections 386 and 387 of the Companies Act 2006 and
- (b) preparing financial statements which give a true and fair view of the state of affairs of the charitable company as at the end of each financial year and of its surplus or deficit for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the charitable company.

These financial statements have been prepared in accordance with the provisions applicable to charitable companies subject to the small companies regime.

The financial statements were approved by the Board of Trustees and authorised for issue on 8 May 2024 and were signed on its behalf by:

Mr C S Kalirai - Trustee

BRITISH NUCLEAR MEDICINE SOCIETY

**CASH FLOW STATEMENT
FOR THE YEAR ENDED 31 DECEMBER 2023**

	Notes	2023 £	2022 £
Cash flows from operating activities			
Cash generated from operations	1	80,923	90,998
		<hr/>	<hr/>
Net cash provided by operating activities		80,923	90,998
		<hr/>	<hr/>
Cash flows from investing activities			
Purchase of tangible fixed assets		(433)	-
Interest received		5,933	1,706
		<hr/>	<hr/>
Net cash provided by investing activities		5,500	1,706
		<hr/>	<hr/>
Change in cash and cash equivalents in the reporting period		86,423	92,704
Cash and cash equivalents at the beginning of the reporting period		346,722	254,018
		<hr/>	<hr/>
Cash and cash equivalents at the end of the reporting period		433,145	346,722
		<hr/> <hr/>	<hr/> <hr/>

The notes form part of these financial statements

BRITISH NUCLEAR MEDICINE SOCIETY

**NOTES TO THE CASH FLOW STATEMENT
FOR THE YEAR ENDED 31 DECEMBER 2023**

1. RECONCILIATION OF NET INCOME TO NET CASH FLOW FROM OPERATING ACTIVITIES			
		2023	2022
		£	£
Net income for the reporting period (as per the Statement of Financial Activities)		91,366	49,702
Adjustments for:			
Depreciation charges		1,147	1,494
Interest received		(5,933)	(1,706)
Decrease in debtors		20,748	14,638
(Decrease)/increase in creditors		(26,405)	26,870
		<u>80,923</u>	<u>90,998</u>
Net cash provided by operations		<u>80,923</u>	<u>90,998</u>
2. ANALYSIS OF CHANGES IN NET FUNDS			
	At 1.1.23	Cash flow	At 31.12.23
	£	£	£
Net cash			
Cash at bank	346,722	86,423	433,145
	<u>346,722</u>	<u>86,423</u>	<u>433,145</u>
Total	<u>346,722</u>	<u>86,423</u>	<u>433,145</u>

The notes form part of these financial statements

BRITISH NUCLEAR MEDICINE SOCIETY

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023

1. ACCOUNTING POLICIES

Basis of preparing the financial statements

The financial statements of the charitable company, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Income

All income is recognised in the Statement of Financial Activities once the charity has entitlement to the funds, it is probable that the income will be received and the amount can be measured reliably.

Exhibition income is recognised in the Statement of Financial Activities in the year that the exhibition is held.

Grants and donations are only recognised in the statement of Financial Activity when the charity has unconditional entitlement to the resources. Where the donor imposes conditions that the resource is expended in a future accounting period, income is recorded as deferred income at the balance sheet date and a creditor is included under deferred income.

Expenditure

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.

Exhibition expense are recognised in the Statement of Financial Activities in the year that the exhibition is held.

Tangible fixed assets

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Fixtures and fittings	- 15% on reducing balance
Computer equipment	- 33% on reducing balance

Taxation

The charity is exempt from corporation tax on its charitable activities.

Fund accounting

Unrestricted funds are available of use at the discretion of the trustees in furtherance of the general objectives of the charity and which have not been designated for other purposes.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors which have been raised by the Charity for particular purposes. The cost of raising and administering such funds are charged against the specific fund.

Further explanation of the nature and purpose of each fund is included in the notes to the financial statements.

Pension costs and other post-retirement benefits

The charitable company operates a defined contribution pension scheme. Contributions payable to the charitable company's pension scheme are charged to the Statement of Financial Activities in the period to which they relate.

BRITISH NUCLEAR MEDICINE SOCIETY

**NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 DECEMBER 2023**

2. DONATIONS AND LEGACIES					
				2023	2022
				£	£
Donations				4,400	3,500
				<u> </u>	<u> </u>
3. OTHER TRADING ACTIVITIES					
				2023	2022
				£	£
Commercial exhibition income				187,021	148,658
Annual conference delegate registration fees				148,480	98,356
Commission received				4,124	169
Royalties received				71,861	72,760
Other project income				1,280	-
				<u> </u>	<u> </u>
				412,766	319,943
				<u> </u>	<u> </u>
4. INVESTMENT INCOME					
				2023	2022
				£	£
Deposit account interest				5,933	1,706
				<u> </u>	<u> </u>
5. RAISING FUNDS					
Raising donations and legacies					
				2023	2022
				£	£
Support costs				141,820	106,165
				<u> </u>	<u> </u>
Other trading activities					
				2023	2022
				£	£
Purchases				239,557	189,112
Awards and prizes				1,432	775
Journal subscriptions				39,488	43,431
				<u> </u>	<u> </u>
				280,477	233,318
				<u> </u>	<u> </u>
Aggregate amounts				422,297	339,483
				<u> </u>	<u> </u>
6. SUPPORT COSTS					
				Management	Finance
				£	£
Raising donations and legacies				133,668	2,934
				<u> </u>	<u> </u>
				Other	Governance
				£	costs
				1,147	£
				<u> </u>	Totals
				4,071	£
				<u> </u>	<u> </u>
				141,820	<u> </u>

BRITISH NUCLEAR MEDICINE SOCIETY

**NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 DECEMBER 2023**

7. NET INCOME/(EXPENDITURE)

Net income/(expenditure) is stated after charging/(crediting):

	2023	2022
	£	£
Other assurance services	3,831	4,383
Depreciation - owned assets	1,146	1,494
	<u>5,977</u>	<u>5,877</u>

8. TRUSTEES' REMUNERATION AND BENEFITS

There were no trustees' remuneration or other benefits for the year ended 31 December 2023 nor for the year ended 31 December 2022.

Trustees' expenses

Payments totalling £4,761 (2022: £1,645) were made to trustees to reimburse travel costs to conferences and council meetings.

9. STAFF COSTS

	2023	2022
	£	£
Wages and salaries	86,558	65,168
Other pension costs	3,079	2,947
	<u>89,637</u>	<u>68,115</u>

The average monthly number of employees during the year was as follows:

	2023	2022
Administrative	<u>3</u>	<u>2</u>

No employees received emoluments in excess of £60,000.

10. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES

	Unrestricted fund £	Restricted fund £	Total funds £
INCOME AND ENDOWMENTS FROM			
Donations and legacies	3,500	-	3,500
Other trading activities	319,943	-	319,943
Investment income	1,666	40	1,706
Other income	64,036	-	64,036
Total	<u>389,145</u>	<u>40</u>	<u>389,185</u>
EXPENDITURE ON			
Raising funds	339,483	-	339,483
NET INCOME	49,662	40	49,702
RECONCILIATION OF FUNDS			
Total funds brought forward	340,720	14,368	355,088
TOTAL FUNDS CARRIED FORWARD	<u>390,382</u>	<u>14,408</u>	<u>404,790</u>

BRITISH NUCLEAR MEDICINE SOCIETY

**NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 DECEMBER 2023**

11. TANGIBLE FIXED ASSETS

	Fixtures and fittings £	Computer equipment £	Totals £
COST			
At 1 January 2023	905	30,102	31,007
Additions	-	432	432
	<hr/>	<hr/>	<hr/>
At 31 December 2023	905	30,534	31,439
	<hr/>	<hr/>	<hr/>
DEPRECIATION			
At 1 January 2023	685	27,193	27,878
Charge for year	33	1,113	1,146
	<hr/>	<hr/>	<hr/>
At 31 December 2023	718	28,306	29,024
	<hr/>	<hr/>	<hr/>
NET BOOK VALUE			
At 31 December 2023	187	2,228	2,415
	<hr/> <hr/>	<hr/> <hr/>	<hr/> <hr/>
At 31 December 2022	220	2,909	3,129
	<hr/> <hr/>	<hr/> <hr/>	<hr/> <hr/>

12. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2023 £	2022 £
Trade debtors	49,542	70,732
Other debtors	39,132	40,428
Prepayments and accrued income	79,851	78,113
	<hr/>	<hr/>
	168,525	189,273
	<hr/> <hr/>	<hr/> <hr/>

13. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2023 £	2022 £
Trade creditors	4,160	5,897
Social security and other taxes	1,959	2,177
VAT	13,989	20,665
Other creditors	82,440	100,959
Accrued expenses	5,381	4,636
	<hr/>	<hr/>
	107,929	134,334
	<hr/> <hr/>	<hr/> <hr/>

14. MOVEMENT IN FUNDS

	At 1.1.23 £	Net movement in funds £	At 31.12.23 £
Unrestricted funds			
General fund	390,382	91,501	481,883
Restricted funds			
Ross Breen Fund	14,408	(135)	14,273
	<hr/>	<hr/>	<hr/>
TOTAL FUNDS	404,790	91,366	496,156
	<hr/> <hr/>	<hr/> <hr/>	<hr/> <hr/>

BRITISH NUCLEAR MEDICINE SOCIETY

**NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 DECEMBER 2023**

14. MOVEMENT IN FUNDS - continued

Net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	513,581	(422,080)	91,501
Restricted funds			
Ross Breen Fund	82	(217)	(135)
TOTAL FUNDS	<u>513,663</u>	<u>(422,297)</u>	<u>91,366</u>

Comparatives for movement in funds

	At 1.1.22 £	Net movement in funds £	At 31.12.22 £
Unrestricted funds			
General fund	340,720	49,662	390,382
Restricted funds			
Ross Breen Fund	14,368	40	14,408
TOTAL FUNDS	<u>355,088</u>	<u>49,702</u>	<u>404,790</u>

Comparative net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	389,145	(339,483)	49,662
Restricted funds			
Ross Breen Fund	40	-	40
TOTAL FUNDS	<u>389,185</u>	<u>(339,483)</u>	<u>49,702</u>

A current year 12 months and prior year 12 months combined position is as follows:

	At 1.1.22 £	Net movement in funds £	At 31.12.23 £
Unrestricted funds			
General fund	340,720	141,163	481,883
Restricted funds			
Ross Breen Fund	14,368	(95)	14,273
TOTAL FUNDS	<u>355,088</u>	<u>141,068</u>	<u>496,156</u>

BRITISH NUCLEAR MEDICINE SOCIETY

**NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 DECEMBER 2023**

14. MOVEMENT IN FUNDS - continued

A current year 12 months and prior year 12 months combined net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	902,726	(761,563)	141,163
Restricted funds			
Ross Breen Fund	122	(217)	(95)
TOTAL FUNDS	<u>902,848</u>	<u>(761,780)</u>	<u>141,068</u>

The Ros Breen Fund was established in memory of Ros Breen, who was Superintendent Radiographer in Nuclear Medicine at Southampton General Hospital. The fund is invested in a capital reserve bank account and the interest earned is then used to provide grants to members of the Technology Group.

15. RELATED PARTY DISCLOSURES

There were no related party transactions for the year ended 31 December 2023.

BRITISH NUCLEAR MEDICINE SOCIETY

**DETAILED STATEMENT OF FINANCIAL ACTIVITIES
FOR THE YEAR ENDED 31 DECEMBER 2023**

	2023 £	2022 £
INCOME AND ENDOWMENTS		
Donations and legacies		
Donations	4,400	3,500
Other trading activities		
Commercial exhibition income	187,021	148,658
Annual conference delegate registration fees	148,480	98,356
Commission received	4,124	169
Royalties received	71,861	72,760
Other project income	1,280	-
	<hr/>	<hr/>
	412,766	319,943
Investment income		
Deposit account interest	5,933	1,706
Other income		
Members subscriptions	90,564	64,036
	<hr/>	<hr/>
Total incoming resources	513,663	389,185
 EXPENDITURE		
Other trading activities		
Scientific meeting expenses	238,607	183,663
Other project expenses	950	5,449
Awards and prizes	1,432	775
Journal subscriptions	39,488	43,431
	<hr/>	<hr/>
	280,477	233,318
Support costs		
Management		
Wages and social security	86,558	65,168
Pensions	3,079	2,947
Rent	1,280	1,265
Insurance	1,033	813
Subscriptions	678	1,332
Telephone	709	517
Postage and stationery	867	615
General meeting and travelling expenses	19,711	7,051
Sundries	355	113
Computer costs	19,398	16,493
Advertising and website costs	-	796
	<hr/>	<hr/>
	133,668	97,110
Finance		
Bank charges	1,681	1,419
Direct debit processing costs	1,253	1,069
	<hr/>	<hr/>
	2,934	2,488
Other		
Fixtures and fittings	33	39
Carried forward	33	39

This page does not form part of the statutory financial statements

BRITISH NUCLEAR MEDICINE SOCIETY

**DETAILED STATEMENT OF FINANCIAL ACTIVITIES
FOR THE YEAR ENDED 31 DECEMBER 2023**

	2023 £	2022 £
Other		
Brought forward	33	39
Computer equipment	1,114	1,455
	<hr/>	<hr/>
	1,147	1,494
 Governance costs		
Auditors' remuneration for non audit work	3,831	4,383
Professional charges	-	450
Payroll costs	240	240
	<hr/>	<hr/>
	4,071	5,073
 Total resources expended	<hr/>	<hr/>
	422,297	339,483
 Net income	<hr/>	<hr/>
	91,366	49,702
	<hr/> <hr/>	<hr/> <hr/>

This page does not form part of the statutory financial statements

BRITISH NUCLEAR MEDICINE SOCIETY

England & Wales - Charity number 1150234

Accounts

REGISTERED COMPANY NUMBER: 08082786 (England and Wales)
REGISTERED CHARITY NUMBER: 1150234

**REPORT OF THE TRUSTEES AND
FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2022
FOR
BRITISH NUCLEAR MEDICINE SOCIETY**

E R Grove & Co Limited
Grove House
Coombs Wood Court
Steel Park Road
Halesowen
West Midlands
B62 8BF

BRITISH NUCLEAR MEDICINE SOCIETY

**CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2022**

	Page
Report of the Trustees	1 to 3
Independent Examiner's Report	4
Statement of Financial Activities	5
Balance Sheet	6
Notes to the Financial Statements	7 to 11
Detailed Statement of Financial Activities	12 to 13

BRITISH NUCLEAR MEDICINE SOCIETY
REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31 DECEMBER 2022

The trustees who are also directors of the charity for the purposes of the Companies Act 2006, present their report with the financial statements of the charity for the year ended 31 December 2022. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).

OBJECTIVES AND ACTIVITIES

Objectives and aims

British Nuclear Medicine Society is dedicated to promoting the multidisciplinary practice of high quality nuclear medicine for the benefit of patients.

The specific objectives of the British Nuclear Medicine Society are to:

- 1 Raise the profile of nuclear medicine
- 2 Engage with all health care providers involved in the clinical use of radionuclides
- 3 Provide a forum for the communication of advances in nuclear medicine
- 4 Provide resources and encourage the provision of education and training to support continuing professional development.
- 5 Represent nuclear medicine with official bodies and on advisory committees
- 6 Develop and promote standards and guidelines for the safe and effective practice of nuclear medicine
- 7 Promote nuclear medicine research and development
- 8 Improve the level of support to isolated departments
- 9 Provide greater information for the benefit of patients
- 10 Promote and support the recertification/revalidation of practitioners
- 11 Maintain an appropriate charitable status.

Significant activities

In order for the charity to achieve its aim BNMS engage in the following activities:

- Raising the profile of nuclear medicine through the website, scientific meetings and attendance of careers fairs.
- Engaging with other professional organisations, including British Institute of Radiology, British Cardiology Society, Institute of Physics and Engineering in Medicine, Royal College of Physicians, Royal College of Radiologists, Royal College of Surgeons, Royal College of Nursing, Society and College of Radiographers and Society of Radiological Protection.
- Providing a forum for the communication of advances in nuclear medicine through annual and regional scientific meetings, Nuclear Medicine Communications (the official BNMS journal) and the BNMS website.
- Leading in the provision of education and training to support the development of nuclear medicine
- Representing the specialty on relevant official bodies and advisory committees
- Developing and promoting standards and guidelines for the safe practice of nuclear medicine.
- Promoting nuclear medicine research and development by engaging with academic institutions and industry to promote research leading to new developments and improvements in clinical practice.

Public benefit

The public benefits from the activities of the British Nuclear Medicine Society through the pursuit of its specific objectives including the development and promotion of standards and guidelines for the safe and effective practice of nuclear medicine, the promotion of nuclear medicine research and development and the provision of greater information for the public on the BNMS website.

BRITISH NUCLEAR MEDICINE SOCIETY

REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31 DECEMBER 2022

ACHIEVEMENT AND PERFORMANCE

Charitable activities

The British Nuclear Medicine Society held three scientific and educational meetings this year around the UK, the results of which are as follows:

	Spring Glasgow £	Autumn Swansea £	Online Educational £	Total £
Income				
Commercial exhibition income	122,576	22,665	3,417	148,658
Annual conference delegate registration fees	77,202	11,783	9,894	98,879
	<hr/>	<hr/>	<hr/>	<hr/>
	199,778	34,448	13,311	247,537
Less: Scientific meeting expenses	162,183	18,185	3,294	183,662
	<hr/>	<hr/>	<hr/>	<hr/>
Surplus	37,595	16,263	10,017	63,875
	<hr/>	<hr/>	<hr/>	<hr/>

Fundraising activities

The British Nuclear Medicine Society generates income from membership fees, from royalties received through "Nuclear Medicine Communications" (the scientific journal of the BNMS) as well registration and exhibitor fees from those attendees at the annual and educational meetings of the Society.

FUTURE PLANS

The society will continue to promote the multidisciplinary practice of nuclear medicine for the benefit of patients. It plans to continue holding regular meetings throughout the country and will further encourage regional networks.

STRUCTURE, GOVERNANCE AND MANAGEMENT

Governing document

The charity is controlled by its governing document, a deed of trust, and constitutes a limited company, limited by guarantee, as defined by the Companies Act 2006.

REFERENCE AND ADMINISTRATIVE DETAILS

Registered Company number

08082786 (England and Wales)

Registered Charity number

1150234

Registered office

Royal College of Physicians
11 St Andrews Place
Regents Park
London
London
NW1 4LE

Trustees

Who are also directors

Mrs J Croasdale

Dr R Graham

Dr S Redman

Dr J R Buscombe (Resigned 17 May 22)

Mr C S Kalirai (appointed 17 May 22)

Radiopharmacist

Radiologist

Radiologist

Nuclear Medicine Physician

Clinical Scientist


Independent Examiner

E R Grove & Co Limited
Grove House
Coombs Wood Court
Steel Park Road
Halesowen
West Midlands
B62 8BF

Approved by order of the board of trustees on 23 May 2023 and signed on its behalf by:

BRITISH NUCLEAR MEDICINE SOCIETY

**REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31 DECEMBER 2022**

A handwritten signature in black ink, appearing to read 'C. Kalirai', written in a cursive style.

Mr C S Kalirai - Trustee

INDEPENDENT EXAMINER'S REPORT TO THE TRUSTEES OF BRITISH NUCLEAR MEDICINE SOCIETY

Independent examiner's report to the trustees of British Nuclear Medicine Society ('the Company')

I report to the charity trustees on my examination of the accounts of the Company for the year ended 31 December 2022.

Responsibilities and basis of report

As the charity's trustees of the Company (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under Section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under Section 145(5) (b) of the 2011 Act.

Independent examiner's statement

Since your charity's gross income exceeded £250,000 your examiner must be a member of a listed body. I can confirm that I am qualified to undertake the examination because I am a member of the Institute of Chartered Accountants in England and Wales, which is one of the listed bodies.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

1. accounting records were not kept in respect of the Company as required by Section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of Section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities (applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.



Steven Lomas

E R Grove & Co Limited
Grove House
Coombs Wood Court
Steel Park Road
Halesowen
West Midlands
B62 8BF

23 May 2023

BRITISH NUCLEAR MEDICINE SOCIETY

**STATEMENT OF FINANCIAL ACTIVITIES
FOR THE YEAR ENDED 31 DECEMBER 2022**

	Notes	Unrestricted fund £	Restricted fund £	2022 Total funds £	2021 Total funds £
INCOME AND ENDOWMENTS FROM					
Donations and legacies		3,500	-	3,500	-
Other trading activities	2	319,943	-	319,943	138,522
Investment income	3	1,666	40	1,706	835
Other income		64,036	-	64,036	61,192
Total		<u>389,145</u>	<u>40</u>	<u>389,185</u>	<u>200,549</u>
 EXPENDITURE ON					
Raising funds	4	339,483	-	339,483	171,070
 NET INCOME					
		49,662	40	49,702	29,479
 RECONCILIATION OF FUNDS					
Total funds brought forward		340,720	14,368	355,088	325,609
TOTAL FUNDS CARRIED FORWARD		<u><u>390,382</u></u>	<u><u>14,408</u></u>	<u><u>404,790</u></u>	<u><u>355,088</u></u>

The notes form part of these financial statements

BRITISH NUCLEAR MEDICINE SOCIETY

**BALANCE SHEET
31 DECEMBER 2022**

	Notes	Unrestricted fund £	Restricted fund £	2022 Total funds £	2021 Total funds £
FIXED ASSETS					
Tangible assets	9	3,129	-	3,129	4,623
CURRENT ASSETS					
Debtors	10	189,273	-	189,273	203,911
Cash at bank		332,314	14,408	346,722	254,018
		<u>521,587</u>	<u>14,408</u>	<u>535,995</u>	<u>457,929</u>
CREDITORS					
Amounts falling due within one year	11	(134,334)	-	(134,334)	(107,464)
NET CURRENT ASSETS		<u>387,253</u>	<u>14,408</u>	<u>401,661</u>	<u>350,465</u>
TOTAL ASSETS LESS CURRENT LIABILITIES		<u>390,382</u>	<u>14,408</u>	<u>404,790</u>	<u>355,088</u>
NET ASSETS		<u>390,382</u>	<u>14,408</u>	<u>404,790</u>	<u>355,088</u>
FUNDS	12				
Unrestricted funds				390,382	340,720
Restricted funds				14,408	14,368
TOTAL FUNDS				<u>404,790</u>	<u>355,088</u>

The charitable company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2022.


The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2022 in accordance with Section 476 of the Companies Act 2006.

The trustees acknowledge their responsibilities for

- (a) ensuring that the charitable company keeps accounting records that comply with Sections 386 and 387 of the Companies Act 2006 and
- (b) preparing financial statements which give a true and fair view of the state of affairs of the charitable company as at the end of each financial year and of its surplus or deficit for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the charitable company.

These financial statements have been prepared in accordance with the provisions applicable to charitable companies subject to the small companies regime.

The financial statements were approved by the Board of Trustees and authorised for issue on 23 May 2023 and were signed on its behalf by:



Mr C S Kalirai - Trustee

BRITISH NUCLEAR MEDICINE SOCIETY

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2022

1. ACCOUNTING POLICIES

Basis of preparing the financial statements

The financial statements of the charitable company, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Income

All income is recognised in the Statement of Financial Activities once the charity has entitlement to the funds, it is probable that the income will be received and the amount can be measured reliably.

Exhibition income is recognised in the Statement of Financial Activities in the year that the exhibition is held.

Expenditure

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.

Exhibition expense are recognised in the Statement of Financial Activities in the year that the exhibition is held.

Tangible fixed assets

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Fixtures and fittings	- 15% on reducing balance
Computer equipment	- 33% on reducing balance

Taxation

The charity is exempt from corporation tax on its charitable activities.

Fund accounting

Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees.

Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

Further explanation of the nature and purpose of each fund is included in the notes to the financial statements.

Pension costs and other post-retirement benefits

The charitable company operates a defined contribution pension scheme. Contributions payable to the charitable company's pension scheme are charged to the Statement of Financial Activities in the period to which they relate.

2. OTHER TRADING ACTIVITIES

	2022	2021
	£	£
Commercial exhibition income	148,658	35,417
Annual conference delegate registration fees	98,356	36,589
Commission received	169	955
Royalties received	72,760	65,594
Other project income	-	(33)
	<u>319,943</u>	<u>138,522</u>

BRITISH NUCLEAR MEDICINE SOCIETY

**NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 DECEMBER 2022**

3. INVESTMENT INCOME			
		2022	2021
		£	£
Deposit account interest		<u>1,706</u>	<u>835</u>
4. RAISING FUNDS			
Raising donations and legacies			
		2022	2021
		£	£
Support costs		<u>106,165</u>	<u>93,783</u>
5. NET INCOME/(EXPENDITURE)			
Net income/(expenditure) is stated after charging/(crediting):			
		2022	2021
		£	£
Other assurance services		4,383	4,600
Depreciation - owned assets		<u>1,494</u>	<u>2,217</u>
6. TRUSTEES' REMUNERATION AND BENEFITS			
There were no trustees' remuneration or other benefits for the year ended 31 December 2022 nor for the year ended 31 December 2021.			
7. STAFF COSTS			
The average monthly number of employees during the year was as follows:			
		2022	2021
Administrative		<u>2</u>	<u>2</u>
No employees received emoluments in excess of £60,000.			
8. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES			
	Unrestricted fund £	Restricted fund £	Total funds £
INCOME AND ENDOWMENTS FROM			
Other trading activities	138,517	5	138,522
Investment income	834	1	835
Other income	<u>61,192</u>	-	<u>61,192</u>
Total	<u>200,543</u>	<u>6</u>	<u>200,549</u>
EXPENDITURE ON			
Raising funds	<u>171,070</u>	-	<u>171,070</u>
NET INCOME	29,473	6	29,479
RECONCILIATION OF FUNDS			
Total funds brought forward	<u>311,247</u>	<u>14,362</u>	<u>325,609</u>
TOTAL FUNDS CARRIED FORWARD	<u>340,720</u>	<u>14,368</u>	<u>355,088</u>

BRITISH NUCLEAR MEDICINE SOCIETY

**NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 DECEMBER 2022**

9. TANGIBLE FIXED ASSETS

	Fixtures and fittings £	Computer equipment £	Totals £
COST			
At 1 January 2022 and 31 December 2022	905	30,102	31,007
DEPRECIATION			
At 1 January 2022	646	25,738	26,384
Charge for year	39	1,455	1,494
At 31 December 2022	685	27,193	27,878
NET BOOK VALUE			
At 31 December 2022	220	2,909	3,129
At 31 December 2021	259	4,364	4,623

10. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2022 £	2021 £
Trade debtors	70,732	31,897
Other debtors	40,428	101,618
Prepayments and accrued income	78,113	70,396
	<u>189,273</u>	<u>203,911</u>

11. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2022 £	2021 £
Trade creditors	5,897	35,147
Social security and other taxes	2,177	2,435
VAT	20,665	2,388
Other creditors	100,959	63,591
Accrued expenses	4,636	3,903
	<u>134,334</u>	<u>107,464</u>

12. MOVEMENT IN FUNDS

	At 1.1.22 £	Net movement in funds £	At 31.12.22 £
Unrestricted funds			
General fund	340,720	49,662	390,382
Restricted funds			
Ross Breen Fund	14,368	40	14,408
TOTAL FUNDS	<u>355,088</u>	<u>49,702</u>	<u>404,790</u>

BRITISH NUCLEAR MEDICINE SOCIETY

**NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 DECEMBER 2022**

12. MOVEMENT IN FUNDS - continued

Net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	389,145	(339,483)	49,662
Restricted funds			
Ross Breen Fund	40	-	40
TOTAL FUNDS	<u>389,185</u>	<u>(339,483)</u>	<u>49,702</u>

Comparatives for movement in funds

	At 1.1.21 £	Net movement in funds £	At 31.12.21 £
Unrestricted funds			
General fund	311,247	29,473	340,720
Restricted funds			
Ross Breen Fund	14,362	6	14,368
TOTAL FUNDS	<u>325,609</u>	<u>29,479</u>	<u>355,088</u>

Comparative net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	200,543	(171,070)	29,473
Restricted funds			
Ross Breen Fund	6	-	6
TOTAL FUNDS	<u>200,549</u>	<u>(171,070)</u>	<u>29,479</u>

A current year 12 months and prior year 12 months combined position is as follows:

	At 1.1.21 £	Net movement in funds £	At 31.12.22 £
Unrestricted funds			
General fund	311,247	79,135	390,382
Restricted funds			
Ross Breen Fund	14,362	46	14,408
TOTAL FUNDS	<u>325,609</u>	<u>79,181</u>	<u>404,790</u>

BRITISH NUCLEAR MEDICINE SOCIETY

**NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 DECEMBER 2022**

12. MOVEMENT IN FUNDS - continued

A current year 12 months and prior year 12 months combined net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	589,688	(510,553)	79,135
Restricted funds			
Ros Breen Fund	46	-	46
TOTAL FUNDS	<u>589,734</u>	<u>(510,553)</u>	<u>79,181</u>

The Ros Breen Fund was established in memory of Ros Breen, who was Superintendent Radiographer in Nuclear Medicine at Southampton General Hospital. The fund is invested in a capital reserve bank account and the interest earned is then used to provide grants to members of the Technology Group.

13. RELATED PARTY DISCLOSURES

There were no related party transactions for the year ended 31 December 2022.

BRITISH NUCLEAR MEDICINE SOCIETY

England & Wales - Charity number 1150234

Accounts

REGISTERED COMPANY NUMBER: 08082786 (England and Wales)
REGISTERED CHARITY NUMBER: 1150234

**REPORT OF THE TRUSTEES AND
FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2021
FOR
BRITISH NUCLEAR MEDICINE SOCIETY**

E R Grove & Co Limited
Grove House
Coombs Wood Court
Steel Park Road
Halesowen
West Midlands
B62 8BF

BRITISH NUCLEAR MEDICINE SOCIETY

**CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2021**

	Page
Report of the Trustees	1 to 3
Independent Examiner's Report	4
Statement of Financial Activities	5
Balance Sheet	6
Notes to the Financial Statements	7 to 12

**REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31 DECEMBER 2021**

The trustees who are also directors of the charity for the purposes of the Companies Act 2006, present their report with the financial statements of the charity for the year ended 31 December 2021. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).

OBJECTIVES AND ACTIVITIES

Objectives and aims

British Nuclear Medicine Society is dedicated to promoting the multidisciplinary practice of high quality nuclear medicine for the benefit of patients.

The specific objectives of the British Nuclear Medicine Society are to:

- 1 Raise the profile of nuclear medicine
- 2 Engage with all health care providers involved in the clinical use of radionuclides
- 3 Provide a forum for the communication of advances in nuclear medicine
- 4 Provide resources and encourage the provision of education and training to support continuing professional development.
- 5 Represent nuclear medicine with official bodies and on advisory committees
- 6 Develop and promote standards and guidelines for the safe and effective practice of nuclear medicine
- 7 Promote nuclear medicine research and development
- 8 Improve the level of support to isolated departments
- 9 Provide greater information for the benefit of patients
- 10 Promote and support the recertification/revalidation of practitioners
- 11 Maintain an appropriate charitable status.

Significant activities

In order for the charity to achieve its aim BNMS engage in the following activities:

- Raising the profile of nuclear medicine through the website, scientific meetings and attendance of careers fairs.
- Engaging with other professional organisations, including British Institute of Radiology, British Cardiology Society, Institute of Physics and Engineering in Medicine, Royal College of Physicians, Royal College of Radiologists, Royal College of Surgeons, Royal College of Nursing, Society and College of Radiographers and Society of Radiological Protection.
- Providing a forum for the communication of advances in nuclear medicine through annual and regional scientific meetings, Nuclear Medicine Communications (the official BNMS journal) and the BNMS website.
- Leading in the provision of education and training to support the development of nuclear medicine
- Representing the specialty on relevant official bodies and advisory committees
- Developing and promoting standards and guidelines for the safe practice of nuclear medicine.
- Promoting nuclear medicine research and development by engaging with academic institutions and industry to promote research leading to new developments and improvements in clinical practice.

Public benefit

The public benefits from the activities of the British Nuclear Medicine Society through the pursuit of its specific objectives including the development and promotion of standards and guidelines for the safe and effective practice of nuclear medicine, the promotion of nuclear medicine research and development and the provision of greater information for the public on the BNMS website.

REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31 DECEMBER 2021

ACHIEVEMENT AND PERFORMANCE

Charitable activities

The British Nuclear Medicine Society held two scientific and educational meetings this year around the UK, the results of which are as follows:

	Spring Virtual £	Autumn Virtual £	Total £
Income			
Commercial exhibition income	18,200	17,217	35,417
Annual conference delegate registration fees	15,805	20,784	36,589
	<u>34,005</u>	<u>38,001</u>	<u>72,005</u>
Less: Scientific meeting expenses	11,965	17,256	29,221
Surplus	<u>22,040</u>	<u>20,745</u>	<u>42,784</u>

Fundraising activities

The British Nuclear Medicine Society generates income from membership fees, from royalties received through "Nuclear Medicine Communications" (the scientific journal of the BNMS) as well registration and exhibitor fees from those attendees at the annual and educational meetings of the Society.

Covid-19 Pandemic

The onset of the Pandemic caused significant disruption to the society's operations and scientific meetings.

The charity has introduced a few changes to our working practices to safeguard our employees and trustees. These include, closing the head office and moving to home working.

We are pleased that membership numbers have been steady during the year and that most of the costs scientific meetings that were cancelled, were recovered by the charity for future meetings.

The ongoing pandemic brings continued uncertainty to the wider economy and our own operations. However, the trustees are confident the charity is well placed to deal with these challenges.

FUTURE PLANS

The society will continue to promote the multidisciplinary practice of nuclear medicine for the benefit of patients. It plans to continue holding regular meetings throughout the country and will further encourage regional networks.

STRUCTURE, GOVERNANCE AND MANAGEMENT

Governing document

The charity is controlled by its governing document, a deed of trust, and constitutes a limited company, limited by guarantee, as defined by the Companies Act 2006.

REFERENCE AND ADMINISTRATIVE DETAILS

Registered Company number

08082786 (England and Wales)

Registered Charity number

1150234

Registered office

Royal College of Physicians
11 St Andrews Place
Regents Park
London
London
NW1 4LE

Trustees

Who are also directors

Mrs J Croasdale	Radiopharmacist
Dr R Graham	Radiologist
Dr S Redman	Clinical Scientist
Dr J R Buscombe	Nuclear Medicine Physician

**REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31 DECEMBER 2021**

REFERENCE AND ADMINISTRATIVE DETAILS

Independent Examiner

E R Grove & Co Limited
Grove House
Coombs Wood Court
Steel Park Road
Halesowen
West Midlands
B62 8BF

Approved by order of the board of trustees on 17 May 2022 and signed on its behalf by:

Dr J R Buscombe - Trustee

INDEPENDENT EXAMINER'S REPORT TO THE TRUSTEES OF BRITISH NUCLEAR MEDICINE SOCIETY

Independent examiner's report to the trustees of British Nuclear Medicine Society ('the Company')

I report to the charity trustees on my examination of the accounts of the Company for the year ended 31 December 2021.

Responsibilities and basis of report

As the charity's trustees of the Company (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5) (b) of the 2011 Act.

Independent examiner's statement

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

1. accounting records were not kept in respect of the Company as required by section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities (applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

Steven Lomas
Senior Statutory Auditor
E R Grove & Co Limited
Grove House
Coombs Wood Court
Steel Park Road
Halesowen
West Midlands
B62 8BF

17 May 2022

BRITISH NUCLEAR MEDICINE SOCIETY
STATEMENT OF FINANCIAL ACTIVITIES
FOR THE YEAR ENDED 31 DECEMBER 2021

	Notes	Unrestricted fund £	Restricted fund £	2021 Total funds £	2020 Total funds £
INCOME AND ENDOWMENTS FROM					
Other trading activities	2	138,517	5	138,522	82,144
Investment income	3	834	1	835	1,304
Other income		<u>61,192</u>	<u>-</u>	<u>61,192</u>	<u>69,981</u>
Total		<u>200,543</u>	<u>6</u>	<u>200,549</u>	<u>153,429</u>
EXPENDITURE ON					
Raising funds	4	171,070	-	171,070	170,544
NET INCOME/(EXPENDITURE)		<u>29,473</u>	<u>6</u>	<u>29,479</u>	<u>(17,115)</u>
RECONCILIATION OF FUNDS					
Total funds brought forward		311,247	14,362	325,609	342,724
TOTAL FUNDS CARRIED FORWARD		<u>340,720</u>	<u>14,368</u>	<u>355,088</u>	<u>325,609</u>

The notes form part of these financial statements

BRITISH NUCLEAR MEDICINE SOCIETY (REGISTERED NUMBER: 08082786)

**BALANCE SHEET
31 DECEMBER 2021**

	Notes	Unrestricted fund £	Restricted fund £	2021 Total funds £	2020 Total funds £
FIXED ASSETS					
Tangible assets	9	4,623	-	4,623	6,724
CURRENT ASSETS					
Debtors	10	203,911	-	203,911	151,916
Cash at bank		<u>239,650</u>	<u>14,368</u>	<u>254,018</u>	<u>232,712</u>
		443,561	14,368	457,929	384,628
CREDITORS					
Amounts falling due within one year	11	(107,464)	-	(107,464)	(65,743)
NET CURRENT ASSETS		<u>336,097</u>	<u>14,368</u>	<u>350,465</u>	<u>318,885</u>
TOTAL ASSETS LESS CURRENT LIABILITIES		340,720	14,368	355,088	325,609
NET ASSETS FUNDS	12	<u>340,720</u>	<u>14,368</u>	<u>355,088</u>	<u>325,609</u>
Unrestricted funds				340,720	311,247
Restricted funds				<u>14,368</u>	<u>14,362</u>
TOTAL FUNDS				<u>355,088</u>	<u>325,609</u>

The charitable company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2021.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2021 in accordance with Section 476 of the Companies Act 2006.

The trustees acknowledge their responsibilities for

- (a) ensuring that the charitable company keeps accounting records that comply with Sections 386 and 387 of the Companies Act 2006 and
- (b) preparing financial statements which give a true and fair view of the state of affairs of the charitable company as at the end of each financial year and of its surplus or deficit for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the charitable company.

These financial statements have been prepared in accordance with the provisions applicable to charitable companies subject to the small companies regime.

The financial statements were approved by the Board of Trustees and authorised for issue on 17 May 2022 and were signed on its behalf by:

Dr J R Buscombe - Trustee

BRITISH NUCLEAR MEDICINE SOCIETY

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2021

1. ACCOUNTING POLICIES

Basis of preparing the financial statements

The financial statements of the charitable company, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Income

All income is recognised in the Statement of Financial Activities once the charity has entitlement to the funds, it is probable that the income will be received and the amount can be measured reliably.

Exhibition income is recognised in the Statement of Financial Activities in the year that the exhibition is held.

Expenditure

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.

Exhibition expense are recognised in the Statement of Financial Activities in the year that the exhibition is held.

Tangible fixed assets

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Fixtures and fittings	- 15% on reducing balance
Computer equipment	- 33% on reducing balance

Taxation

The charity is exempt from corporation tax on its charitable activities.

Fund accounting

Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees.

Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

Further explanation of the nature and purpose of each fund is included in the notes to the financial statements.

Pension costs and other post-retirement benefits

The charitable company operates a defined contribution pension scheme. Contributions payable to the charitable company's pension scheme are charged to the Statement of Financial Activities in the period to which they relate.

2. OTHER TRADING ACTIVITIES

	2021	2020
	£	£
Commercial exhibition income	35,417	4,500
Annual conference delegate registration fees	36,589	5,900
Commission received	955	856
Royalties received	65,594	70,617
Other project income	(33)	271
	<u>138,522</u>	<u>82,144</u>

BRITISH NUCLEAR MEDICINE SOCIETY

**NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 DECEMBER 2021**

3.	INVESTMENT INCOME	2021	2020
		£	£
	Deposit account interest	<u>835</u>	<u>1,304</u>

4.	RAISING FUNDS	2021	2020
	Raising donations and legacies	£	£
	Support costs	<u>93,783</u>	<u>114,832</u>

5.	NET INCOME/(EXPENDITURE)	2021	2020
	Net income/(expenditure) is stated after charging/(crediting):	£	£
	Other assurance services	4,600	5,000
	Depreciation - owned assets	2,217	3,446
	Deficit on disposal of fixed assets	<u>-</u>	<u>248</u>

6. TRUSTEES' REMUNERATION AND BENEFITS

There were no trustees' remuneration or other benefits for the year ended 31 December 2021 nor for the year ended 31 December 2020.

Trustees' expenses

Expenses of £1,355 (2019: £6,135) were paid to the trustees during the year.

7. STAFF COSTS

The average monthly number of employees during the year was as follows:

		2021	2020
	Administrative	<u>2</u>	<u>3</u>

No employees received emoluments in excess of £60,000.

8.	COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES	Unrestricted fund £	Restricted fund £	Total funds £
	INCOME AND ENDOWMENTS FROM			
	Other trading activities	82,144	-	82,144
	Investment income	1,291	13	1,304
	Other Income	<u>69,981</u>	-	<u>69,981</u>
	Total	<u>153,416</u>	<u>13</u>	<u>153,429</u>
	EXPENDITURE ON			
	Raising funds	170,544	-	170,544
	NET INCOME/(EXPENDITURE)	<u>(17,128)</u>	<u>13</u>	<u>(17,115)</u>

BRITISH NUCLEAR MEDICINE SOCIETY

**NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 DECEMBER 2021**

8. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES - continued	Unrestricted fund £	Restricted fund £	Total funds £
RECONCILIATION OF FUNDS			
Total funds brought forward	328,375	14,349	342,724
TOTAL FUNDS CARRIED FORWARD	<u>311,247</u>	<u>14,362</u>	<u>325,609</u>
9. TANGIBLE FIXED ASSETS	Fixtures and fittings £	Computer equipment £	Totals £
COST			
At 1 January 2021	789	30,102	30,891
Additions	116	-	116
At 31 December 2021	<u>905</u>	<u>30,102</u>	<u>31,007</u>
DEPRECIATION			
At 1 January 2021	611	23,556	24,167
Charge for year	35	2,182	2,217
At 31 December 2021	<u>646</u>	<u>25,738</u>	<u>26,384</u>
NET BOOK VALUE			
At 31 December 2021	<u>259</u>	<u>4,364</u>	<u>4,623</u>
At 31 December 2020	<u>178</u>	<u>6,546</u>	<u>6,724</u>
10. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR		2021 £	2020 £
Trade debtors		31,897	2,773
Other debtors		101,618	60,015
VAT		-	15,067
Prepayments and accrued income		<u>70,396</u>	<u>74,061</u>
		<u>203,911</u>	<u>151,916</u>

BRITISH NUCLEAR MEDICINE SOCIETY

**NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 DECEMBER 2021**

11. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2021 £	2020 £
Trade creditors	35,147	51,736
Social security and other taxes	2,435	66
VAT	2,388	-
Other creditors	63,591	10,941
Accrued expenses	<u>3,903</u>	<u>3,000</u>
	<u>107,464</u>	<u>65,743</u>

12. MOVEMENT IN FUNDS

	At 1.1.21 £	Net movement in funds £	At 31.12.21 £
Unrestricted funds			
General fund	311,247	29,473	340,720
Restricted funds			
Ross Breen Fund	14,362	6	14,368
TOTAL FUNDS	<u>325,609</u>	<u>29,479</u>	<u>355,088</u>

Net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	200,543	(171,070)	29,473
Restricted funds			
Ross Breen Fund	6	-	6
TOTAL FUNDS	<u>200,549</u>	<u>(171,070)</u>	<u>29,479</u>

Comparatives for movement in funds

	At 1.1.20 £	Net movement in funds £	At 31.12.20 £
Unrestricted funds			
General fund	328,375	(17,128)	311,247
Restricted funds			
Ross Breen Fund	14,349	13	14,362
TOTAL FUNDS	<u>342,724</u>	<u>(17,115)</u>	<u>325,609</u>

BRITISH NUCLEAR MEDICINE SOCIETY

**NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 DECEMBER 2021**

12. MOVEMENT IN FUNDS - continued

Comparative net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	153,416	(170,544)	(17,128)
Restricted funds			
Ross Breen Fund	13	-	13
TOTAL FUNDS	<u>153,429</u>	<u>(170,544)</u>	<u>(17,115)</u>

A current year 12 months and prior year 12 months combined position is as follows:

	At 1.1.20 £	Net movement in funds £	At 31.12.21 £
Unrestricted funds			
General fund	328,375	12,345	340,720
Restricted funds			
Ross Breen Fund	14,349	19	14,368
TOTAL FUNDS	<u>342,724</u>	<u>12,364</u>	<u>355,088</u>

A current year 12 months and prior year 12 months combined net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	353,959	(341,614)	12,345
Restricted funds			
Ross Breen Fund	19	-	19
TOTAL FUNDS	<u>353,978</u>	<u>(341,614)</u>	<u>12,364</u>

The Ros Breen Fund was established in memory of Ros Breen, who was Superintendent Radiographer in Nuclear Medicine at Southampton General Hospital. The fund is invested in a capital reserve bank account and the interest earned is then used to provide grants to members of the Technology Group.

BRITISH NUCLEAR MEDICINE SOCIETY

**NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 DECEMBER 2021**

13. RELATED PARTY DISCLOSURES

There were no related party transactions for the year ended 31 December 2021.

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.

BRITISH NUCLEAR MEDICINE SOCIETY

England & Wales - Charity number 1150234

Accounts

REGISTERED COMPANY NUMBER: 08082786 (England and Wales)
REGISTERED CHARITY NUMBER: 1150234

**REPORT OF THE TRUSTEES AND
FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2020
FOR
BRITISH NUCLEAR MEDICINE SOCIETY**

E R Grove & Co Limited
Grove House
Coombs Wood Court
Steel Park Road
Halesowen
West Midlands
B62 8BF

BRITISH NUCLEAR MEDICINE SOCIETY

**CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2020**

	Page
Report of the Trustees	1 to 3
Independent Examiner's Report	4
Statement of Financial Activities	5
Balance Sheet	6
Notes to the Financial Statements	7 to 12

**REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31 DECEMBER 2020**

The trustees who are also directors of the charity for the purposes of the Companies Act 2006, present their report with the financial statements of the charity for the year ended 31 December 2020. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).

OBJECTIVES AND ACTIVITIES

Objectives and aims

British Nuclear Medicine Society is dedicated to promoting the multidisciplinary practice of high quality nuclear medicine for the benefit of patients.

The specific objectives of the British Nuclear Medicine Society are to:

- 1 Raise the profile of nuclear medicine
- 2 Engage with all health care providers involved in the clinical use of radionuclides
- 3 Provide a forum for the communication of advances in nuclear medicine
- 4 Provide resources and encourage the provision of education and training to support continuing professional development.
- 5 Represent nuclear medicine with official bodies and on advisory committees
- 6 Develop and promote standards and guidelines for the safe and effective practice of nuclear medicine
- 7 Promote nuclear medicine research and development
- 8 Improve the level of support to isolated departments
- 9 Provide greater information for the benefit of patients
- 10 Promote and support the recertification/revalidation of practitioners
- 11 Maintain an appropriate charitable status.

Significant activities

In order for the charity to achieve its aim BNMS engage in the following activities:

- Raising the profile of nuclear medicine through the website, scientific meetings and attendance of careers fairs.
- Engaging with other professional organisations, including British Institute of Radiology, British Cardiology Society, Institute of Physics and Engineering in Medicine, Royal College of Physicians, Royal College of Radiologists, Royal College of Surgeons, Royal College of Nursing, Society and College of Radiographers and Society of Radiological Protection.
- Providing a forum for the communication of advances in nuclear medicine through annual and regional scientific meetings, Nuclear Medicine Communications (the official BNMS journal) and the BNMS website.
- Leading in the provision of education and training to support the development of nuclear medicine
- Representing the specialty on relevant official bodies and advisory committees
- Developing and promoting standards and guidelines for the safe practice of nuclear medicine.
- Promoting nuclear medicine research and development by engaging with academic institutions and industry to promote research leading to new developments and improvements in clinical practice.

Public benefit

The public benefits from the activities of the British Nuclear Medicine Society through the pursuit of its specific objectives including the development and promotion of standards and guidelines for the safe and effective practice of nuclear medicine, the promotion of nuclear medicine research and development and the provision of greater information for the public on the BNMS website.

REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31 DECEMBER 2020

ACHIEVEMENT AND PERFORMANCE

Charitable activities

The British Nuclear Medicine Society held three scientific and educational meetings this year around the UK, the results of which are as follows:

	Liverpool (cancelled) £	Virtual £	Total £
Income			
Commercial exhibition income	-	4,500	4,500
Annual conference delegate registration fees	-	5,900	5,900
	-	10,400	10,400
Less: Scientific meeting expenses	489	-7,307	-7,917
Surplus / (deficit)	-489	3,093	2,484

Fundraising activities

The British Nuclear Medicine Society generates income from membership fees, from royalties received through "Nuclear Medicine Communications" (the scientific journal of the BNMS) as well registration and exhibitor fees from those attendees at the annual and educational meetings of the Society.

Covid-19 Pandemic

The onset of the Pandemic caused significant disruption to the society's operations and scientific meetings.

The charity has introduced a few changes to our working practices to safeguard our employees and trustees. These include, closing the head office and moving to home working. Reducing the number of staff from three to two.

The charity made the difficult decision to cancel our annual spring meeting in Liverpool and convert our move our autumn meeting in Leeds to an online meeting.

We are pleased that membership numbers have been steady during the year and that most of the costs scientific meetings that were cancelled, were recovered by the charity for future meetings.

The ongoing pandemic brings continued uncertainty to the wider economy and our own operations. However, the trustees are confident the charity is well placed to deal with these challenges.

FUTURE PLANS

The society will continue to promote the multidisciplinary practice of nuclear medicine for the benefit of patients. It plans to continue holding regular meetings throughout the country and will further encourage regional networks.

STRUCTURE, GOVERNANCE AND MANAGEMENT

Governing document

The charity is controlled by its governing document, a deed of trust, and constitutes a limited company, limited by guarantee, as defined by the Companies Act 2006.

REFERENCE AND ADMINISTRATIVE DETAILS

Registered Company number

08082786 (England and Wales)

Registered Charity number

1150234

Registered office

Royal College of Physicians
11 St Andrews Place
Regents Park
London
London
NW1 4LE

**REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31 DECEMBER 2020**

Trustees

Mrs J Croasdale Radiopharmacist
Dr R Graham Radiologist
Dr S Redman Clinical Scientist
Mr C S Kalirai Nuclear Medicine Physician
Dr J R Buscombe Nuclear Medicine Physician
Mr N Gulliver Nuclear Medicine Technologist (resigned 23.9.20)
Dr Y Du Nuclear Medicine Physician (resigned 23.9.20)
Dr F X Sundram Physician
Dr A G Irwin Clinical Scientist
Mr C Mayes Trustee (appointed 23.9.20)
Dr A Parthipun Trustee (appointed 23.9.20)

Independent Examiner

E R Grove & Co Limited
Grove House
Coombs Wood Court
Steel Park Road
Halesowen
West Midlands
B62 8BF

Approved by order of the board of trustees on 23 March 2021 and signed on its behalf by:

Dr J R Buscombe - Trustee

**INDEPENDENT EXAMINER'S REPORT TO THE TRUSTEES OF
BRITISH NUCLEAR MEDICINE SOCIETY**

Independent examiner's report to the trustees of British Nuclear Medicine Society ('the Company')

I report to the charity trustees on my examination of the accounts of the Company for the year ended 31 December 2020.

Responsibilities and basis of report

As the charity's trustees of the Company (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5) (b) of the 2011 Act.

Independent examiner's statement

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

1. accounting records were not kept in respect of the Company as required by section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities (applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

Steven Lomas
Senior Statutory Auditor
E R Grove & Co Limited
Grove House
Coombs Wood Court
Steel Park Road
Halesowen
West Midlands
B62 8BF

23 March 2021

BRITISH NUCLEAR MEDICINE SOCIETY
STATEMENT OF FINANCIAL ACTIVITIES
FOR THE YEAR ENDED 31 DECEMBER 2020

	Notes	Unrestricted fund £	Restricted fund £	2020 Total funds £	2019 Total funds £
INCOME AND ENDOWMENTS FROM					
Donations and legacies		-	-	-	42
Other trading activities	2	82,144	-	82,144	272,789
Investment income	3	1,291	13	1,304	1,839
Other income		69,981	-	69,981	51,512
Total		<u>153,416</u>	<u>13</u>	<u>153,429</u>	<u>326,182</u>
EXPENDITURE ON					
Raising funds	4	170,544	-	170,544	297,129
NET INCOME/(EXPENDITURE)		<u>(17,128)</u>	<u>13</u>	<u>(17,115)</u>	<u>29,053</u>
RECONCILIATION OF FUNDS					
Total funds brought forward		328,375	14,349	342,724	313,671
TOTAL FUNDS CARRIED FORWARD		<u><u>311,247</u></u>	<u><u>14,362</u></u>	<u><u>325,609</u></u>	<u><u>342,724</u></u>

The notes form part of these financial statements

BALANCE SHEET
31 DECEMBER 2020

	Notes	Unrestricted fund £	Restricted fund £	2020 Total funds £	2019 Total funds £
FIXED ASSETS					
Tangible assets	9	6,724	-	6,724	8,614
CURRENT ASSETS					
Debtors	10	151,916	-	151,916	156,905
Cash at bank		218,350	14,362	232,712	271,401
		<u>370,266</u>	<u>14,362</u>	<u>384,628</u>	<u>428,306</u>
CREDITORS					
Amounts falling due within one year	11	(65,743)	-	(65,743)	(94,196)
		<u>304,523</u>	<u>14,362</u>	<u>318,885</u>	<u>334,110</u>
NET CURRENT ASSETS					
		<u>311,247</u>	<u>14,362</u>	<u>325,609</u>	<u>342,724</u>
TOTAL ASSETS LESS CURRENT LIABILITIES					
		<u>311,247</u>	<u>14,362</u>	<u>325,609</u>	<u>342,724</u>
NET ASSETS					
		<u>311,247</u>	<u>14,362</u>	<u>325,609</u>	<u>342,724</u>
FUNDS					
	12			311,247	328,375
Unrestricted funds				14,362	14,349
Restricted funds				<u>325,609</u>	<u>342,724</u>
TOTAL FUNDS					
				<u>325,609</u>	<u>342,724</u>

The charitable company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2020.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2020 in accordance with Section 476 of the Companies Act 2006.

The trustees acknowledge their responsibilities for

- (a) ensuring that the charitable company keeps accounting records that comply with Sections 386 and 387 of the Companies Act 2006 and
- (b) preparing financial statements which give a true and fair view of the state of affairs of the charitable company as at the end of each financial year and of its surplus or deficit for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the charitable company.

These financial statements have been prepared in accordance with the provisions applicable to charitable companies subject to the small companies regime.

The financial statements were approved by the Board of Trustees and authorised for issue on 23 March 2021 and were signed on its behalf by:

Dr J R Buscombe - Trustee

BRITISH NUCLEAR MEDICINE SOCIETY
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2020

1. ACCOUNTING POLICIES

Basis of preparing the financial statements

The financial statements of the charitable company, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Income

All income is recognised in the Statement of Financial Activities once the charity has entitlement to the funds, it is probable that the income will be received and the amount can be measured reliably.

Exhibition income is recognised in the Statement of Financial Activities in the year that the exhibition is held.

Expenditure

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.

Exhibition expense are recognised in the Statement of Financial Activities in the year that the exhibition is held.

Tangible fixed assets

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Fixtures and fittings	- 15% on reducing balance
Computer equipment	- 33% on reducing balance

Taxation

The charity is exempt from corporation tax on its charitable activities.

Fund accounting

Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees.

Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

Further explanation of the nature and purpose of each fund is included in the notes to the financial statements.

Pension costs and other post-retirement benefits

The charitable company operates a defined contribution pension scheme. Contributions payable to the charitable company's pension scheme are charged to the Statement of Financial Activities in the period to which they relate.

2. OTHER TRADING ACTIVITIES

	2020	2019
	£	£
Commercial exhibition income	4,500	111,313
Annual conference delegate registration fees	5,900	88,295
Commission received	856	870
Royalties received	70,617	68,775
Other project income	271	3,536
	<u>82,144</u>	<u>272,789</u>

BRITISH NUCLEAR MEDICINE SOCIETY

**NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 DECEMBER 2020**

3. INVESTMENT INCOME

	2020	2019
	£	£
Deposit account interest	<u>1,304</u>	<u>1,839</u>

4. RAISING FUNDS

Raising donations and legacies

	2020	2019
	£	£
Support costs	<u>114,832</u>	<u>104,235</u>

5. NET INCOME/(EXPENDITURE)

Net income/(expenditure) is stated after charging/(crediting):

	2020	2019
	£	£
Other assurance services	5,000	3,150
Depreciation - owned assets	3,446	4,238
Deficit on disposal of fixed assets	<u>248</u>	<u>-</u>

6. TRUSTEES' REMUNERATION AND BENEFITS

There were no trustees' remuneration or other benefits for the year ended 31 December 2020 nor for the year ended 31 December 2019.

Trustees' expenses

Expenses of £1,355 (2019: £6,135) were paid to the trustees during the year.

7. STAFF COSTS

The average monthly number of employees during the year was as follows:

	2020	2019
Administrative	<u>3</u>	<u>3</u>

No employees received emoluments in excess of £60,000.

8. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES

	Unrestricted fund £	Restricted fund £	Total funds £
INCOME AND ENDOWMENTS FROM			
Donations and legacies	42	-	42
Other trading activities	272,789	-	272,789
Investment income	1,811	28	1,839
Other income	<u>51,512</u>	<u>-</u>	<u>51,512</u>
Total	326,154	28	326,182
 EXPENDITURE ON			
Raising funds	<u>297,129</u>	<u>-</u>	<u>297,129</u>
NET INCOME	29,025	28	29,053

BRITISH NUCLEAR MEDICINE SOCIETY

**NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 DECEMBER 2020**

8. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES - continued

	Unrestricted fund £	Restricted fund £	Total funds £
RECONCILIATION OF FUNDS			
Total funds brought forward	299,350	14,321	313,671
TOTAL FUNDS CARRIED FORWARD	<u>328,375</u>	<u>14,349</u>	<u>342,724</u>

9. TANGIBLE FIXED ASSETS

	Fixtures and fittings £	Computer equipment £	Totals £
COST			
At 1 January 2020	789	30,944	31,733
Additions	-	1,883	1,883
Disposals	-	(2,725)	(2,725)
At 31 December 2020	<u>789</u>	<u>30,102</u>	<u>30,891</u>
DEPRECIATION			
At 1 January 2020	579	22,540	23,119
Charge for year	32	3,414	3,446
Eliminated on disposal	-	(2,398)	(2,398)
At 31 December 2020	<u>611</u>	<u>23,556</u>	<u>24,167</u>
NET BOOK VALUE			
At 31 December 2020	<u>178</u>	<u>6,546</u>	<u>6,724</u>
At 31 December 2019	<u>210</u>	<u>8,404</u>	<u>8,614</u>

10. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2020 £	2019 £
Trade debtors	2,773	65,351
Other debtors	60,015	19,310
VAT	15,067	-
Prepayments and accrued income	74,061	72,244
	<u>151,916</u>	<u>156,905</u>

BRITISH NUCLEAR MEDICINE SOCIETY

**NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 DECEMBER 2020**

11. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2020 £	2019 £
Trade creditors	51,736	19,074
Social security and other taxes	66	-
VAT	-	7,119
Other creditors	10,941	65,003
Accrued expenses	3,000	3,000
	<u>65,743</u>	<u>94,196</u>

12. MOVEMENT IN FUNDS

	At 1.1.20 £	Net movement in funds £	At 31.12.20 £
Unrestricted funds			
General fund	328,375	(17,128)	311,247
Restricted funds			
Ross Breen Fund	14,349	13	14,362
	<u>342,724</u>	<u>(17,115)</u>	<u>325,609</u>

Net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	153,416	(170,544)	(17,128)
Restricted funds			
Ross Breen Fund	13	-	13
	<u>153,429</u>	<u>(170,544)</u>	<u>(17,115)</u>

Comparatives for movement in funds

	At 1.1.19 £	Net movement in funds £	At 31.12.19 £
Unrestricted funds			
General fund	299,350	29,025	328,375
Restricted funds			
Ross Breen Fund	14,321	28	14,349
	<u>313,671</u>	<u>29,053</u>	<u>342,724</u>

BRITISH NUCLEAR MEDICINE SOCIETY

**NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 DECEMBER 2020**

12. MOVEMENT IN FUNDS - continued

Comparative net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	326,154	(297,129)	29,025
Restricted funds			
Ross Breen Fund	28	-	28
TOTAL FUNDS	<u>326,182</u>	<u>(297,129)</u>	<u>29,053</u>

A current year 12 months and prior year 12 months combined position is as follows:

	At 1.1.19 £	Net movement in funds £	At 31.12.20 £
Unrestricted funds			
General fund	299,350	11,897	311,247
Restricted funds			
Ross Breen Fund	14,321	41	14,362
TOTAL FUNDS	<u>313,671</u>	<u>11,938</u>	<u>325,609</u>

A current year 12 months and prior year 12 months combined net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	479,570	(467,673)	11,897
Restricted funds			
Ross Breen Fund	41	-	41
TOTAL FUNDS	<u>479,611</u>	<u>(467,673)</u>	<u>11,938</u>

The Ros Breen Fund was established in memory of Ros Breen, who was Superintendent Radiographer in Nuclear Medicine at Southampton General Hospital. The fund is invested in a capital reserve bank account and the interest earned is then used to provide grants to members of the Technology Group.

BRITISH NUCLEAR MEDICINE SOCIETY

**NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 DECEMBER 2020**

13. RELATED PARTY DISCLOSURES

There were no related party transactions for the year ended 31 December 2020.